In spring 2016, the FDA released the long-awaited draft guidelines that brought generic drug manufacturers into the abuse-deterrent formulations market. This new regulatory framework comes at a time when public concerns about abuse of prescription opioids has never been higher � and yet obstacles to market uptake remain due to payer and prescriber hesitancy.

Date : 6th November 2017 to 7th November 2017

Place : United States, Washington

Website :https://www.eventbrite.com/e/4th-human-abuse-liability-abuse-deterrent-formulations-exl-tickets-34323184569?aff=NDT

Contact Person:Paula Edwards

Description:

In spring 2016, the FDA released the long-awaited draft guidelines that brought generic drug manufacturers into the abuse-deterrent formulations market. This new regulatory framework comes at a time when public concerns about abuse of prescription opioids has never been higher — and yet obstacles to market uptake remain due to payer and prescriber hesitancy.

In spring 2016, the FDA released the long-awaited draft guidelines that brought generic drug manufacturers into the abuse-deterrent formulations market. This new regulatory framework comes at a time when public concerns about abuse of prescription opioids has never been higher � and yet obstacles to market uptake remain due to payer and prescriber hesitancy. will be held in Washington,United States on date 2017-11-07

---

Deadline for abstracts/proposals : 2nd November 2017

Keynote Speakers :

Conference Highlights :Insight on the latest regulatory guidelines for branded and generic opioids Lessons learned from FDA advisory committee meetings State-of-the-art reviews of prodrug technologies, agonist/antagonist formulations and novel delivery mechanisms Techniques to find and document the data showing the uptake and abuse rate of specific opioid types A way forward to make the case to payers, patients and physicians that your opioids are truly less of an abuse risk

Venue :Washington, D.C., DC, United States

Check the event website for more details.